Vitor Asseituno 宋伟明

See you at the live event TODAY ✨ How to Leverage a Fractional CAIO Use this link https://lnkd.in/e_7e9UVR #ai #webinar #caio #cio #healthcareinnovation #events #whitehousepolicy #patientsafety #healthtech

2

Funding vs impact —  what wins at the HRX Pitch Competition? Here’s an all-in review of 11 cardiac tech trailazers: Empallo  I  Claire Beskin, Ruizhi (Ray) Liao ↳  Key milestones: ▪️  Proprietary AI-guided system for heart failure management ▪️  Network of 10+ sponsors and partners ▪️  Identification of key clinical predictors of mortality ↳  Results & impact: ▪️  48-hour data is proven to predict discharge treatment response   iCardio.ai  I  Joseph Sokol ↳  Key milestones: ▪️  FDA Breakthrough Designation for automated detection of aortic stenosis ▪️  8 distributors and industry collabs with NVIDIA, Viz.ai, UltraLinQ etc. ▪️  Dataset of 200M+ images for AI model training ↳  Results & impact: No data Carelog  I  Aman Alok ↳  Key milestones: ▪️  The world’s first breakthrough ECG AI model ▪️  1m+ ECG signals from 100k+ patients for model training ▪️  7 partner orgs for external validation  ▪️  4 live deployments in collab with ECG manufacturers ↳  Results & impact: ▪️  0.80+ AUROC score on all algorithms, outperforming industry standards SeeMedX  I  Deborah Simpson ↳  Key milestones: ▪️  Non-invasive monitoring tech for congestive heart failure ▪️  HIPAA compliance ↳ Results & impact: No data Hylomorph  I  Simone Bottan ↳  Key milestones: ▪️  Unique biomaterial coating reducing fibrotic reactions to medical implants ▪️  Collabs with leading medical institutions and companies ↳ Results & impact: ▪️  Preclinical testing proved reduction in fibrotic encapsulation Cardiosense  I  Andrew Carek, Amit Gupta ↳  Key milestones: ▪️  FDA Breakthrough Device designation ▪️  AI-powered digital biomarkers for early disease detection ▪️  10+ industry partnersships ↳  Results & impact: No data Proton Intelligence  I  Sahan Ranamukhaarachchi ↳  Key milestones: ▪️  First ever on-demand potassium monitoring ▪️  Allows patients with dangerous K+ levels to receive treatments safely ↳ Results & impact: No data nucleusRx  I  Projit Aon ↳  Key milestones: ▪️  Real-time patient insights  ▪️  Tools for proactive remote intervention ↳ Results & impact: No data HrtEx  I  Vivek Bhalla ↳  Key milestones: ▪️ A proprietary digital tech for chronic disease management ▪️ Developed through Stanford Biodesign Innovation program ↳ Results & impact: No data Third Coast Dynamics  I  Bradley Allen, Michael Markl ↳  Key milestones: ▪️  AI-powered tech providing hemodynamic imaging biomarkers ↳ Results & impact: No data KardioDiagnostix Inc.  I  Mohammed Shameer Iqbal ↳  Key milestones: ▪️  Flagship product for next-gen non-invasive cardiac imaging tech ↳ Results & impact: No data ↓↓↓ The takeaway? Less than 30% can demonstrate proven results. Don’t get me wrong — I’m cheering for health tech. And yet, I can’t wait to see how these innovations will change the game. P.S. Who else deserves shoutout in cardiac tech space?

15

2 comentários

If you're a femtech or healthtech founder raising money, don't forget to consider non-dilutive funding opportunities! Venture capital money isn't right for every company, and even if you raise VC funds, you may need additional sources of funding and financing during bridge periods. Non-dilutive funding opportunities, such as grants, can be particularly beneficial and allow you to retain control over your company while continuing to scale. If you're curious about the types of non-dilutive funding available, where to find these opportunities, and how to incorporate them into your fundraising strategy, join FemInnovation, G2G - Innovative Government Affairs Consulting, and Health Collaboration Partners on June 26th at 12:00 pm EST for a FREE webinar discussing these topics! David Lee and Greg Kapcar will share incredible insights that you won't want to miss. Sign up links are in the comments. Can't make it to the webinar but want to catch the replay? Be sure to sign up for the FemInnovator Community (use coupon code FREEMEMBERSHIP) to access all of our webinars and resources on-demand. #femtech #healthtech #fundraising

66

6 comentários

Q1 2024 was big for Digital Health, with $1.1B in VC funding. A large portion came from major deals like $126M for Transcarent and $108.8M for Rightway. Despite some challenges in digital therapeutics and telehealth, investments in general care ($213.4M) and health benefits navigation ($140.7M) are promising. Read what’s driving the shift from direct-to-consumer to enterprise telehealth models here: https://ow.ly/uNYs50SpXGh

28

2 comentários

AI advances in healthcare are accelerating. In March, the 2nd conference on AI and Health will be in Lisbon. Take a look at all the topics, amazing to see the expanse. There is also a call for papers if you are interested in presenting. Who's going? https://lnkd.in/eGp6xeca #generativeai

4

I saw this pattern of rapid growth and then consolidation happening in banking and FinTech in the mid 2000s. We jumped into Digital Healthcare in 2016 with the thesis that there were similar drivers. One big surprise, COVID, acted as rocket fuel to the industry but the same fundamentals apply. Consolidation of the biggest players , innovation by faster moving startups raising capital and then being acquired and patients expecting current ( i.e... wait, we are still using faxes? ) but rather now , de facto to them, omni channel consumer experiences. What can we continue to learn from past "explosions" of growth?

2

📢 Calling all healthcare innovators to join MIT Solve's Health Equity Challenge! Half the world lacks access to comprehensive health services, and two billion people face financial hardships due to healthcare costs. We at Verge believe that healthtech innovations can change that, and so does MIT Solve. MIT Solve is calling for innovators worldwide to submit their technology-driven solutions that improve healthcare access and outcomes in an affordable, scalable, and sustainable way, especially in under-resourced communities. 🔍 What's MIT Solve Looking For? - Ensuring ethical and effective health-related data collection for AI  - Strengthening health system capacity & resilience - Increasing access and quality of health services for underserved groups around the world 🏆 Why Participate? - Prize funding - 9-month support program - Tailored workshops, coaching & more! 📆 Don't miss out on this opportunity to make a difference because the deadline is TOMORROW: April 23, 2024, 12:00 PM EDT. Check out more details here: https://lnkd.in/g8cGEfid #HealthcareInnovation #HealthcareAccess #Innovation #GlobalHealth #SocialImpact #HealthEquity #HealthEquityChallege Verge HealthTech Fund

3

3 comentários

🚀 Digital Health Funding Soars by 48% in Q1'24! In Q1'24, digital health saw an impressive 48% increase in funding compared to the previous quarter. This surge outpaces the broader venture capital landscape, which recorded an 11% growth. While digital health was on the rise, other industries experienced more moderate gains or even declines: - Fintech: -16% QoQ - Retail Tech: +17% QoQ This uptick in digital health funding highlights the growing interest in technology-driven healthcare solutions. It's a sign that investors are recognising the potential for innovation and positive impact within this sector, even as other industries face more mixed outcomes. 🌱💰 #DigitalHealth #VentureCapital #StartupFunding #Innovation

4

What is "Digital Health"? Here is the FDA's definition, which I believe is a very good one! "The broad scope of digital health includes categories such as mobile health (mHealth), health information technology (IT), wearable devices, telehealth and telemedicine, and personalized medicine. From mobile medical apps and software that support the clinical decisions doctors make every day to artificial intelligence and machine learning, digital technology has been driving a revolution in health care. Digital health tools have the vast potential to improve our ability to accurately diagnose and treat disease and to enhance the delivery of health care for the individual. Digital health technologies use computing platforms, connectivity, software, and sensors for health care and related uses. These technologies span a wide range of uses, from applications in general wellness to applications as a medical device. They include technologies intended for use as a medical product, in a medical product, as companion diagnostics, or as an adjunct to other medical products (devices, drugs, and biologics). They may also be used to develop or study medical products." MedTech Innovator MedTech Innovator Asia Pacific BioTools Innovator LSI Y Combinator Techstars Company Ventures

26

2 comentários

What's happening in healthtech IPOs? 👉🏼 20 digital health companies went public in 2021. 👉🏼 2 went public in 2022 (including Akili). 👉🏼 0 went public in 2023. 👉🏼 ??? in 2024. Three companies give us hope. Let's meet them and ask the question on everyone's mind: who's next? 1️⃣ Waystar just announced plans for a $1B IPO, potentially making it the biggest IPO so far this year. That's 45 million shares for $20-$23 each, valuing the company at nearly $4B on the high end. The company's mission is to simplify healthcare payments for their 30,000+ clients doing 5B+ annual transactions on the platform. It's a pretty diversified client base, considering their top 10 clients account for ~11% of total revenues. But what I find pretty striking is the fact that they process $1.2 TRILLION in gross claims volume spanning HALF of patients in the US. [1,2] 👥 Leadership: Matt Hawkins (CEO), Ric Sinclair (CBO), Steve Oreskovich (CFO), Missy Miller (CMO), Anthony Carrozzella (CGO), John Driscoll (Chairman of the Board) 2️⃣ Tempus AI is looking to go public later this year. The company provides data and analytics tools for precision medicine in areas like oncology (most data and revenue), radiology and cardiology. To date, their offerings have been used by ~95% of the largest public pharma companies and 7,000 physicians across hundreds of provider networks (65% of all academic medical centers in the US). What I find most mind-numbing is that Tempus now has more than 200 PETA-bytes of data in their cloud, which includes 900 million documents and 7.7 million clinical records used to train their multi-modal LLMs. "Between our sequencing and data collection efforts, we are connected in some way to more than 50% of all oncologists practicing in the United States." [3,4] 👥 Leadership: Eric Lefkofsky (CEO, Chairman), Ryan Fukushima (COO), Terron Bruner (CCO), Kate Sasser (CSO), Shane Colley (CTO), Jim Rogers (CFO) 3️⃣ BrightSpring went public back in January. It did not go to plan (shares fell 15%), but has since recovered. BrightSpring delivers complementary pharmacy and provider services to complex patients in lower-cost home and community settings. The company operates in 50 states, serving more than 400,000 patients daily through its approximately 10,000 clinical providers and pharmacists across 9,500 locations. "Our model focuses on delivering high-touch and coordinated services to medically complex clients and patients, which is a large, growing, and underserved population in the U.S. healthcare system." [5,6] 👥 Leadership: Jon Rousseau (CEO, Chairman), Jim Mattingly (CFO), Susan Sender (CCO), Charles Wardrip (CDIO) *** Will we see more digital health IPOs in 2024? Will biotech remain the brightest spot of them all? Let us know what you think! 👇🏼 -- Sources: [1] https://lnkd.in/erXf86YW [2] https://lnkd.in/eMCk7ARq [3] https://lnkd.in/eZaYR9bS [4] https://lnkd.in/ezXEgqdv [5] https://lnkd.in/eKvU6x94 [6] https://lnkd.in/e7E7Pp3t

21

1 comentário

💰Tempus AI Raises a massive $410 Million in IPO ! Rock solid entry at Nasdaq with shares jumping 8% - strong market push for AI in medicine 🔬 Key numbers of Tempus AI Tempus provides AI and data analytics tools for precision medicine across oncology, neuropsychiatry, radiology, and cardiology. More than 7,000 physicians in 2,000 hospital systems, including 65% of all U.S. academic medical centers, use Tempus' platform. The company collaborates with major pharma companies like Pfizer, GSK, and AstraZeneca. 💉 Impressive Growth and Collaborations Tempus employs about 2,300 people and generated $532 million in revenue in 2023. The company raised $1.3 billion over nine funding rounds, with a valuation of $8.1 billion in 2023. Tempus acquired AKESOgen, Highline Sciences, and Arterys over the past 5 years. Investors include Google, Baillie Gifford, Franklin Templeton, NEA, and T. Rowe Price. 🧪 Transforming Healthcare with AI Founded in 2015 by Eric Lefkofsky, Tempus aims to advance precision medicine using AI. The mission is to ensure patients receive the right drug at the right time. With a vast library of multimodal data, Tempus provides AI-enabled solutions to physicians, facilitating personalized patient care and the development of optimal therapeutics. Tempus' capabilities span drug discovery and genomic sequencing, initially focusing on oncology and expanding to other medical fields.

66

4 comentários

Founders can benefit from fundraising this fall by leveraging the current market context. According to data findings provided by Peter Walker , median valuations and cash raised for #Seed, #SeriesA, B, and C rounds are provided, offering valuable benchmarks. This data can help #founders set realistic expectations and strategies for their #fundraising efforts.

7

🚀 Pausefika news: 38 Unicorns in 2024: Here’s the Full🦄 list and their valuation according to TechCrunch (see: https://lnkd.in/dW4qkigJ ) Aven - $1 billion, Flo Health Inc. - $1 billion, Altana Technologies - $1 billion Chainguard - $1.12 billion, Harvey - $1.5 billion, Saronic Technologies - $1 billion, Huntress - $1.55 billion, xAI - $24 billion, BillionToOne - $1 billion, Altruist - $1.5 billion, WEKA - $1.6 billion, Farcaster - $1 billion, Sigma Computing - $1.5 billion, Humanity Protocol - $1 billion, Cyera- $1.5 billion, Monad Labs - $3 billion, Nexamp - $1.5 billion, Grow Therapy - $1.4 billion, Cognition AI - $2 billion, Xaira Therapeutics - $2.7 billion, Flip - $1.19 billion, io.net- $1 billion, Perplexity - $1.04 billion, Octane® - $1.11 billion, Celestial AI - $1.2 billion, IntraBio Inc - $1 billion, Liquid Death - $1.4 billion, Blink Health - $1.28 billion, NinjaOne - $1.9 billion, Ascend Elements - $1.61 billion, Lambda - $1.5 billion, EigenLayer - $1.1 billion, Figure - $2.6 billion, Together AI - $1.25 billion, Bugcrowd - $1 billion, ElevenLabs - $1 billion, Quantinuum - $5.3 billion and Zūm - $1.3 billion Despite a challenging venture capital landscape, unicorns are still emerging every month in 2024. 📈 From AI to cybersecurity, health tech, and fintech, innovative startups are breaking through the billion-dollar valuation barrier. According to data from Crunchbase, CB Insights, and Pitchblock, notable new unicorns include Elon Musk’s xAI, which has already reached an astounding $24 billion valuation. Other standouts include AI-driven legal platform Harvey, cybersecurity firm Chainguard, and the fertility-tracking app Flo Health. Join management of innovation enthusiasts - like myself - on Pausefika to discuss about unicorns metrics! #startups #unicorns #innovation #venturecapital #AI #cybersecurity #healthtech #fintech #Pausefika

1

Is 2025 the year of the health tech IPO? There were ~70 late-stage healthcare startups that were at some point considered unicorns ($1bn+ valuation). When it comes to tech startup speculation, I've read predictions from investors that anywhere between 30–80% of the 1,400 unicorn startups in 2022 are no longer worth $1bn. Who knows what the real answer is? The big question is how we setup healthcare companies to grow sustainably to stick around for the next few decades after going public? Whether we like it or not, public companies are eventually valued at the discounted present value of future cash flows. When I review margins by sector for publicly-traded companies produced by NYU Professor Aswath Damodaran, I see a big margin difference between health IT and healthcare services: - Health IT (128 public cos): 48% gross margins; 17% pretax, pre-stock based comp operating margins - Healthcare Services (119 public cos): 14% gross margins, 4% pretax, pre-stock based comp operating margins The challenge is that healthcare is notoriously higher gross dollar, low gross margin relative to consumer tech or SAAS. So much cost is variable to compensate the clinicians performing the work. Can we begin to see tech-enabled healthcare companies achieve 10-20% EBITDA margins when going public? If we can get a few of those, the market will really take off.

76

26 comentários

Big Bets as Health TechFunding Heats Up > StartUp Health Insights https://lnkd.in/e_MhsCe2 $455M worth of funding deals announced last week, including: Flo Health, a London, UK-based fertility-focused period-tracking app, raised $200M from General Atlantic. Spring Health, a New York, NY-based mental health solution for employers and health plans, raised $100M led by Generation Investment Management, with participation from Kinnevik, William K Warren Foundation, RRE, and Northzone. Healx, a Cambridge, UK-based startup using AI to discover new drugs for rare diseases, raised $47M co-led by Atomico and R42. Perceptive, a Boston, MA-based dental AI startup, raised $30M from Pacific Dental Services, Y Combinator, and Ed Zuckerberg. Protembis, an Aachen, Germany-based medtech company developing a next-gen device for protecting the brains of patients who undergo certain heart treatments, raised €20M ($21.8M) from The European Investment Bank (EIB). MedScout, an Austin, TX-based revenue acceleration platform focused on commercial operations for medtech and life sciences companies, raised $15M led by Fulcrum Equity Partners, with participation from Stage 2 and LiveOak Ventures. Guidehealth, a Dallas, TX-based care enablement company using AI to bring value-based care to underserved patients, raised $14M led by Memorial Hermann. Mindera Health, a Vista, CA-based developer of precision medicine solutions for dermatology, raised $14M led by Mountain Group Partners. Noze, a Montreal, QC-based developer of breath-based diagnostics, raised $5M from the Bill & Melinda Gates Foundation. ReadySet Surgical, a Cleveland, OH-based developer of a surgical inventory management solution, raised $3.4M. Wisedocs, a Toronto, ON-based provider of smart tools to review medical records, raised C$4.5M ($3.3M) from CIBC Innovation Banking. Vedapointe, a Clayton, MO-based SaaS platform to help providers navigate value-based care, raised $2.7M. Orchid AI, a Wilmington, DE-based developer of a HIPAA-compliant AI-powered clinical notes solution for mental health clinicians, raised $1.5M from Y Combinator and strategic investors. https://lnkd.in/e_MhsCe2 #HealthTech #DigitalHealth #HealthIT #Funding #VentureCapital #Investment #Growth #Strategy

3

Digital health startup funding was $5.7B in the first 6 months of 2024. Thanks to Rock Health's investment report, the industry is on-pace to raise more funding than 2023, which is a welcome sign for many later-stage healthcare companies. It does feel like more rounds are being filled by existing investors (i.e., insider rounds) these days, but founders need to raise from whoever will invest at a reasonable valuations / limited liquidation preferences. Feels like early 2025 is the target for many digital health companies to go public. For most unprofitable companies, this will allow them to raise additional capital at a IPO and provide liquidity to existing investors. Now the revenue multiple expectations might be lower than what investors want, but that's the market. The median software multiple is 5.2x in the public markets. Obviously pure software companies will generally trade at higher multiples that digital health companies that involve tech-enabled clinician services (i.e., lower gross margins). I think the organizations who trade for a valuation premium will be both incredibly strategic with industry tail-winds (i.e., home-based) and profitable. But that's just my two cents. Thoughts? --- Credit: Rock Health

70

5 comentários

I’m optimistic about the potential of generative AI to reduce provider burnout and improve provider-patient interactions. However, that optimism is tempered by the data that indicates the technology is not quite ready yet. Bright Ventures is interested in digital health founders who understand the realities of provider-patient interactions, and the role technology can play in strengthening clinical outcomes. Which founders and teams are getting this right? Tag them in the comments below.

50

2 comentários

With $8.2B invested into digital health so far, 2024 is shaping up to be a $10-12B annualized investment year. This would make funding comparable to 2023. I suspect with continued venture investment, boards will require exits. One thing I’m particularly interested in is terms of recent acquisitions and growth equity rounds. What type of downside protection (e.g., structure) is not disclosed to media that protects the investor? Will funds who have specifically raised capital to buy stakes in VC-backed companies at significant discounts? And what revenue/EBITDA multiples are looking like for M&A in 2024/2025? Every founder has to spin their story in a positive light when speaking to media. I know this because PR agencies reach out to me about their clients (p.s. I don’t consider myself a member of the media). The private health tech market feels like it could significantly rip or drop in the next 12-24 months. Therefore, my general advice to early-stage founders is to assume you will not raise capital beyond your seed round. If the investor market heats up in 2025, you will have the option to raise a series A at that time if you’ve built a strong business. If you’ve already raised series c or beyond, then one of your goals will be to time the exit (M&A or IPO) appropriately so that you garner an attractive multiple. There are few private health tech startups that have founder board control, can reinvest positive cash flows, and stay private forever. So by necessity of the structure, exits are desired. - - - - Image Credit: Rock Health

58

13 comentários